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INTRODUCTION
Colorectal cancer is the third leading cause of cancer mortality
in Japan, and in 2013, about 48,000 deaths was attributed to this
disease (1). Approximately 25% of colorectal cancer patients will
have metastatic disease at the time of diagnosis, and an additional
50% of patients who initially present with early -stage disease will
subsequently develop metastases over the course of their disease
(2). Metastatic colorectal cancer remains a major public health
problem, and diagnosis of metastatic disease is usually associated
with poor prognosis.
Vascular endothelial growth factors (VEGFs) and their tyrosine
kinase receptors (VEGF-Rs) are central regulators of tumor angio-
genesis and lymphangiogenesis. Thus, VEGF/VEGF-Rs are cru-
cial therapeutic targets in colorectal cancer therapy (3-5). Several
angiogenesis inhibitors targeting VEGF (bevacizumab) and VEGF-
Rs (regorafenib, sorafenib, sunitinib, vandetatnib, pazopanib and
axiinib) have been developed and become an important option for
management of a number of human malignancies.
Regorafenib is the first small molecule inhibitor of VEGF-Rs ap-
proved in 2014 in Japan for the treatment of patients with metas-
tatic colorectal cancer who have progressed after standard thera-
pies (6). In a pivotal randomized phase III study, a statistically
significant prolongation in overall survival was observed in patients
with colorectal cancer who received regorafenib therapy. These
studies also demonstrated a significant improvement in progres-
sion- free survival. Despite the survival benefit of regorafenib for
metastatic colorectal cancer patients, its overall clinical efficacy
remains quite limited. Unfortunately, a significant number of pa-
tients do not respond to VEGF-R inhibitors. Furthermore, the vast
majority of patients who initially respond to VEGF-R-targeting
agents will develop resistance (7-9).
There is increasing evidence that VEGF/VEGF-R inhibitors act
not only on vascular endothelial cells (anti -angiogenic function)
but also on tumor cells that express functional VEGF-Rs (anti -
angiogenesis- independent function) (10-15). For instance, anti -
VEGF monoclonal antibody induces apoptosis resistance, spheroid
formation and migration/invasion activity (13-15). VEGF-R inhibi-
tors accelerate invasion activity in vitro and induces micro- and
distant metastasis in vivo (16, 17). Thus, some of the effects ob-
served with VEGF/VEGF-R targeting therapies could result from
“direct” effects on tumor cells.
However, the direct effects of VEGF/VEGF-R inhibitors on tumor
cells are not yet fully understood. We previously demonstrated that
monoclonal anti -VEGF antibody (bevacizumab) induced a resis-
tance to apoptosis of colon cancer cells (14). In this study, we ex-
amined the direct effects of VEGF-R inhibitor, regorafenib, on
colon cancer cell phenotypes. We found that treatment of colon
cancer HCT116 cells with regorafenib for only 2 days remarkably
increased cell migration and invasion activities. Intriguingly, chronic
exposure to regorafenib for 90 days dramatically increased cell mi-
gration and invasion activities. Furthermore, cells chronically
treated with regorafenib acquired a resistance to hypoxia- induced
apoptosis. These results suggest that loss of VEGF signaling in can-
cer cells may induce the acquired resistance to anti -angiogenic
therapy by gaining two major malignant phenotypes, apoptosis re-
sistance and migration/invasion.
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MATERIALS AND METHODS
Cell culture and treatment
Human colon cancer cell line (HCT116) was maintained in
RPMI1640 medium with 5% fetal bovine serum and antibiotics.
To develop the HCT/rego-short cells, HCT116 cells were treated
with regorafenib at 500 nM (Selleckchem) for 2 days in RPMI1640
medium with 1% fetal bovine serum and antibiotics. For HCT/rego-
long cells, cells were chronically exposed to 500 nM regorafenib
for 90 days in RPMI1640 medium with 1% fetal bovine serum and
antibiotics.
For hypoxic culture conditions, cells were incubated at low con-
fluence and 37 in RPMI1640 medium supplemented with HEPES
buffer (pH 7.4), 1% fetal bovine serum and antibiotics using an
AnaeroPack-Kenki 5% anaerobic system in which O2 was0.2%
(Sugiyamagen, Japan).
Assessment of apoptosis
Apoptotic cells were assessed by imaging of activated caspase
3/7 using CellEvent caspase-3/7 green detection reagent (Molecu-
lar probes), according to the manufacturer’s instruction.
Cell migration and invasion assay
Migration assay was conducted as described by Fan et al. (9)
with minor modifications. Equal numbers (50,000 cells per well) of
cells were suspended in 0.25 ml of 1% RPMI1640-FBS without or
with regorafenib and placed in the top compartment of a 8 μm pore
membrane chambers (BD Biosciences) ; 0.75 ml of 10% RPMI1640-
FBS was added to the bottom compartment. Following 24 h incu-
bation under standard conditions (37/5% CO2), non-migrating
cells were scraped from the top compartment, and cells that had
migrated to the bottom compartment were fixed and stained using
the Hemacolor Rapid staining of blood smear (Merck). Membranes
were excised and mounted on a standard microscope slide. The
numbers of migrated cells were determined from ten random high-
power fields visualized at200 magnification.
Invasion assays were done using a similar protocol with minor
modifications. The inserts used in the invasion assays were coated
with Matrigel (BD Biosciences) and prehydrated with 1% FBS-
supplemented medium for 2 hours before the addition of the cell
suspension. Following 48 h incubation under standard conditions
(37/5% CO2), and the numbers of invading cells were quantified
from ten random high-power fields visualized at200 magnification.
Statistical analysis
Results are expressed as meansS.D. Statistical analyses of data
were done using ANOVA and the Scheffé’s test. P values0.05
was considered significant.
RESULTS
Effect of short- and long-term exposure to regorafenib on hypoxia-
induced apoptosis
We first examined the effect of short - (2 days) and long-term
(90 days) exposure of colon cancer HCT116 cells to regorafenib on
sensitivity to hypoxia- induced apoptosis, since one of the major in
vivo effects of VEGF-R inhibitors is induction of hypoxic stress in
tumors via suppression of angiogenesis (18, 19). HCT116 cells ex-
press all of VEGF-Rs (VEGF-R1 to -R3) and respond to VEGF-R
inhibitor (15).
Cells were treated for 2 days with regorafenib (HCT/rego-short)
or with vehicle (HCT/ctl), then they were exposed to hypoxic
conditions (0.2% O2) for additional 48 h. Control HCT/ctl cells
displayed a high degree of apoptosis (Fig. 1A). HCT/rego-short
cells showed a similar degree of apoptosis (Fig. 1A). In contrast,
HCT116 cells chronically exposed to regorafenib for 90 days (HCT/
rego- long cells) exhibited a marked resistance to the apoptosis,
compared with control HCT/ctl cells (Fig. 1B).
To explore how HCT/rego- long cells became a resistant to
hypoxia- induced apoptosis, we tested a chemical HIF-1α inhibitor
(FM19G11) that effectively inhibited HIF-1α transcriptional activ-
ity under hypoxic conditions in HCT116 cells (14, 15). Inhibition of
HIF-1α in HCT/ctl cells significantly increased hypoxia- induced
apoptosis (Fig. 1B, FM19G11 +). However, blocking of HIF-1α in
HCT/rego- long cells did not significantly increase the apoptosis
(Fig. 1B, FM19G11 +). This is consistent with our previous report
that chronic treatment with foretinib, another type of a VEGF-R ty-
rosine kinase inhibitor, induced a resistance to hypoxia- induced
apoptosis independently of HIF-1α activity (15).
Figure 1. Effect of short - and long- term exposure to regorafenib on
hypoxia - induced apoptosis
(A) Cells treated for 48 h with regorafenib (HCT/rego-short) or DMSO
(HCT/ctl) were exposed to hypoxia (0.2% O2) for additional 48 h, then
apoptotic cells were determined by measuring of activated caspase 3/7
(n=4-5, meansSD). *P0.01., compared with control HCT/ctl cells.
(B) Cells were exposed to hypoxia (0.2% O2) for 48 h in the absence
( -) or presence of HIF-1α inhibitor FG19G11 (+), then apoptotic cells
were determined (n=4, meansSD). *P0.01., compared with the re-
spective control HCT/ctl cells in each group.
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Effect of short-term exposure to regorafenib on cancer cell mi-
gration and invasion activities
We then assessed the effects of short - term treatment with re-
gorafenib on cell migration and invasion activities, since an increase
in migration/invasion capacity is one of typical malignant pheno-
types of cancer cells to escape from deterioration in the tumor en-
vironment (20). A cell migration activity was assessed using a
modified Boyden chamber. Control HCT/ctl cells showed a slight
migration activity (Fig. 2A, B). Intriguingly, treatment with regoraf-
enib for only 2 days markedly increased the migration activity (a
5- fold higher activity than control HCT/ctl cells) (Fig. 2A). We fur-
ther examined the cell invasion activity using a Matrigel invasion
assay. In agreement with activation of migration, invasive activity
of HCT/rego-short cells was increased in 6- fold of HCT/ctl cells
(Fig. 2C, D).
Effect of long-term exposure to regorafenib on cancer cell mi-
gration and invasion activities
We further studied the effects of long-term treatment (for 90
days) with regorafenib on cell migration and invasion activities.
HCT/rego- long cells exhibited a drastic increase in migration ac-
tivity more than 20-fold of HCT/ctl cells (Fig. 3A, B). In consistent
with the increased migration activity, HCT/rego- long cells showed
a dramatic increase in their invasive activity, whereas HCT/ctl cells
did not show the activity (Fig. 3C, D).
DISCUSSION
This study focused on the short - (2 days) and long-term (90
days) effects of VEGF-R inhibitor regorafenib on cancer cells. We
found that short - term inhibition of VEGF-R could increase migra-
tion and invasion activities. Furthermore, chronic blockade of
VEGF-R induced more aggressive phenotypes (apoptotic resistance
and migration/invasion phenotype).
HCT/rego- long cells acquired a resistance to hypoxia- induced
apoptosis, and the resistance was independent of HIF-1α (Fig. 1B).
These results are consistent with our previous report showing
that a chronic exposure to an another type of VEGF-R inhibitor,
foretinib, also induced the apoptosis resistance that did not require
HIF-1α activation (15). By contrast, short - term treatment with
regorafenib (Fig. 1A) and with foretinib (unpublished data) did
not induce the resistance, suggesting that adaptation and/or se-
lection of cancer cells that are resistant to hypoxia occur during
the chronic, but not short - term, blockade of VEGF-R signaling.
Unexpectedly, treatment with regorafenib for only 2 days signifi-
cantly activated cell migration and invasion (Fig. 2). Exposure to
foretinib for 2 days did not significantly activate the migration
(unpublished data), suggesting that regorafenib activates cellular
adaptive signaling pathway(s) more strongly than foretinib. Fur-
ther studies are needed to elucidate the precise molecular mecha-
nism(s) activated by regorafenib.
Based on the present data and recent reports, it is possible that
VEGF/VEGF-R targeting therapies directly inhibit VEGF signal-
ing in tumor cells, which may remodel tumor cell survival signal(s).
In fact, there is increasing evidence that VEGF itself suppresses
Figure 2. Effect of short - term exposure to regorafenib on cancer cell
migration and invasion activities
(A) HCT/ctl and HCT/rego-short cells were used for transwell migra-
tion assay (n=3, meansSD). *P0.01., compared with control HCT/
ctl cells. HPF, high power field.
(B) Representative microphotographs of migrated cells.
(C) HCT/ctl and HCT/rego-short cells were used for transwell invasion
assay (n=3, meansSD). *P0.01., compared with control HCT/ctl
cells. HPF, high power field.
(D) Representative microphotographs of invaded cells.
Figure 3. Effect of long- term exposure to regorafenib on cancer cell
migration and invasion activities
(A) HCT/ctl and HCT/rego- long cells were used for transwell migra-
tion assay (n=4, meansSD). *P0.01., compared with control HCT/
ctl cells. HPF, high power field.
(B) Representative microphotographs of migrated cells.
(C) HCT/ctl and HCT/rego-short cells were used for transwell invasion
assay (n=4, meansSD). *P0.01., compared with control HCT/ctl
cells. HPF, high power field.
(D) Representative microphotographs of invaded cells.
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migration and invasion of tumor cells in vitro (21), and conversely
that inhibition of VEGF signaling accelerated migration and inva-
sion in vitro and metastasis in vivo (21). Recently, two groups clearly
elucidated how inhibition of VEGF signaling in tumor cells in-
creases migration and invasion (22, 23). VEGF-R interacts with
HGF receptor c-Met, a pro- invasive receptor, and inhibits c-Met
activity by VEGF stimulation. Thus, blockade of VEGF/VEGF-R
activates c-Met, leading to increased migration and invasion (22,
23). These and our findings suggest that over the long term inhi-
bition of VEGF signaling, such remodeling results in adaptation to
VEGF inhibition, and this adaptive response may represent one of
potential mechanism of acquired resistance to VEGF/VEGF-R
targeting therapies.
VEGF/VEGF-R initially held great promise as a therapeutic tar-
get in cancer. In fact, VEGF/VEGF-R-targeting therapy has been
shown to be very effective in certain tumor types, such as renal cell
carcinoma (24, 25). However, the overall benefit of blocking VEGF
activity in other solid tumors is marginal and has led to some skep-
ticism in the field. Therefore, molecular mechanism(s) activated by
chronic loss of VEGF signaling in cancer cells will need to be elu-
cidated to improve and further develop VEGF-targeting therapies.
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